1. Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5
   Pengming Pan et al, 2023, Journal of Medicinal Chemistry CrossRef
2. Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines
   Falko Lange et al, 2014, BioMed Research International CrossRef
3. Transforming growth factor-β downregulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling
   Lili Du et al, 2019, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
4. Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain
   Yan Wu et al, 2023, ACS Central Science CrossRef
5. Capsaicin Induces Apoptosis in KSHV-Positive Primary Effusion Lymphoma by Suppressing ERK and p38 MAPK Signaling and IL-6 Expression
   Misato Moriguchi et al, 2019, Frontiers in Oncology CrossRef
6. Cell lines of human melanoma and their xenograft with braf or nras mutations a targets for targeted therapy. Reviews
   I. N. Mikhaylova et al, 2019, Russian Journal of Biotherapy CrossRef
7. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
   Woo-Jeong Jeong, 2014, World Journal of Gastroenterology CrossRef
8. Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids
   Pradip Shahi Thakuri et al, 2016, Molecular Pharmaceutics CrossRef
9. Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
   Xuguang Zhu et al, 2018, Oncotarget CrossRef
10. Targeted drug combination therapy design based on driver genes
    Lilian Zsákai et al, 2019, Oncotarget CrossRef
11. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
    Ziyao Wang et al, 2022, Frontiers in Oncology CrossRef
12. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib
    Xinyue Zhang et al, 2024, Cureus CrossRef
13. Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation
    Sh. Hashemzadeh et al, 2019, Interdisciplinary Sciences: Computational Life Sciences CrossRef